Ophthalmology

The goal, principle and scheme of the medical therapeutic experiment:

A medical therapeutic experiment is a multi-stage procedure aimed at applying an innovative method of treatment, technology or an innovative therapeutic preparation, which is not a standard therapy for a given illness. The medical therapeutic experiment is an alternative for patients who have not yet been treated or previous treatment has not produced the desired therapeutic effects. The main goal of the medical therapeutic experiment is to improve the patient’s health. The use of MSC therapy as part of a medical therapeutic experiment must always be supported by the consent of the Bioethical Commission at the District Medical Chamber in Częstochowa, Poland.

What are stem cells obtained from Wharton jelly?

Wharton’s jelly-derived mesenchymal stem cells – WJ-MSC are a population of multipotent stem cells, located in the umbilical cord, classified as gelatinous connective tissue.
Wharton jelly is made up mainly of mucopolysaccharides, including hyaluronic acid and chondroitin sulphate.
The mesenchymal stem cells used in the experiment have a fibroblast structure, show adhesion to plastic substrates and originate from unrelated and incompatible in the antigen range of tissue compliance and the main groups and Rh blood factor, donor.

Title of the medical therapeutic experiment:

“The use of mesenchymal cells obtained from a Wharton jelly incompatible donor unrelated to the treatment of patients with ophthalmologic diseases in which there is no causative treatment and in which the treatment did not bring any improvement in the clinical condition.”

Who can take part in a medical therapeutic experiment in the field of ophthalmology?

  • Optic nerve hypoplasia

A disorder associated with optic nerve hypopnea, which is the most common congenital defect. This disorder is manifested in the fact that the optic nerve disc has an unnaturally small size, which is the result of improperly developed certain axons of the optic nerve. Hypolasia of the optic nerve is often correlated with deficiencies of various hormones, delays in development and degenerations in the brain structure.

  • Optic neuropathy

Neuropathy is defined as a group of eye diseases, where the nerve responsible for transferring pulses from the retina of the eye to the visual centers in the brain occurs. The disturbed nerve does not return to full efficiency even after completely reducing the factor responsible for its damage.

  • Stargardt’s disease

Retinal macular disease inherited in an autosomal recessive manner involving both eyes. The ABCR gene is responsible for the occurrence of this disease. The disease consists in the loss of photoreceptors and pigment epithelium in the macula.

  • Optic neuropathy with a demyelination character (Acute demyelinating optic neuritis)

The process causing damage to the myelin sheaths, affecting their proper functioning. In place of the damaged myelin, glial tissue is formed, destabilizing the correct nerve conduction in the optic fibers.

  • Retinal pigmental degeneration (retinitis pigmentosa)

A disease that originated in adolescence, associated with the storage of pigment in the retina of the eye. Secondary may be circulatory disorders within the retina and progressive deterioration of vision, associated with retinal atrophy. In the initial phase, only atrophy of photoreceptors and retinal pigment epithelium are observed. With the progression of the disease, there are also changes within the inner layers of the cells.

  • Cone-Rod Dystrophy

Is an inherited retinal spot disease affecting both eyes. It consists in a fragmentary damage to some of the functions of suppositories and retinal stains in the macula. Inheritance of this disease can be done in an autosomal recessive, autosomal dominant or coupled with the X chromosome.

  • Optic nerve atrophy

A disease resulting from the loss of nerve fibers. An ascending disorder can be isolated where damage to the retina nerve fibers occurs first followed by optic nerve fibers and descending disappearance, in which the optic nerve is damaged due to pathological changes occurring in the skull cavity or in the orbit.

General criteria for the selection of patients receiving therapy using WJ-MSC (Wharton’s jelly mesenchymal stem cells – Wharton jelly stem cells).

  • patients of both sexes,
  • age: from 5 to 85,
  • the obligation to use contraception during the course of therapy (applies to women).

Exclusion criteria from therapy:

  • pregnancy and breast-feeding,
  • severe or acute organ damage,
  • an infectious disease, e.g. HIV, HBV, HCV, HPV,
  • active infection requiring treatment,
  • severe mental disorders,
  • presence of malignant tumor,
  • unstable state of the cardiovascular system,
  • allergy to some antibiotics.

How can you qualify for MSC Therapy?

Patients are asked to send the following documents:

  • hospital treatment information with confirmation of diagnosis,
  • Laboratory results: quality HCV RNA, borrelia IGG and IGM by western-blot, anti HBs, HIV,
  • Hepatitis B vaccination record

to the following address: komorki@cm-klara.pl or by post: Centrum Medyczne Klara, MSC Therapy, ul. Wał Dwernickiego 43/45, 42-202 Częstochowa, Poland where initial verification will take place.

After doctor qualification for MSC Therapy, Klara Medical Center acts on behalf of the Patient for the Bioethical Commission at the District Medical Chamber in Częstochowa, Poland.
At this stage, patients wait for the application to be reviewed by the Bioethical Commission.
In the case of a positively examined application, Klara Medical Center contacts the patient in order to provide information on:

  • application dates
  • the cost of therapy
  • additional tests required
  • organizational information

Diagram of a medical treatment experiment:

As part of the approval of the Bioethical Commission, the patient can receive up to 10 administrations of MSC. The duration of therapy is about 1.5 years.

  • The interval between single administrations is 4-6 weeks – assessment of the treatment effect before each single injection.
  • After the fifth administration of MSC, the patient starts a 6-month break, unless there are medical grounds for continuing therapy without taking into account the interruption.
  • After the end of the 6-month interval, the therapy is resumed for a further 1-5 applications at intervals of 4-6 weeks or once every three months, if the patient’s condition has improved – assessment of the treatment effect before each single injection.

Frequently Asked Questions:

  • How long is the hospitalization at Klara Medical Center?

The patient spends 3 days in the hospital.
Day 1 – admission to the ward
Day 2 – administration of the MSC preparation
Day 3 – hospital discharge in the morning hours

  • Can a parent / guardian or family member stay with the patient while in the hospital?

Yes, the cost in included.

If you would like to receive more information about stem cells treatment, please contact us at:

komorki@cm-klara.pl and / or +48 34 534 5003

Contact